Gondi Christopher S, Lakka Sajani S, Yanamandra Niranjan, Olivero William C, Dinh Dzung H, Gujrati Meena, Tung C H, Weissleder Ralph, Rao Jasti S
Program of Cancer Biology and Department of Biomedical and Therapeutic Sciences, University of Illinois College of Medicine, Peoria, 61656, USA.
Cancer Res. 2004 Jun 15;64(12):4069-77. doi: 10.1158/0008-5472.CAN-04-1243.
We have shown previously that urokinase plasminogen activator receptor (uPAR) and cathepsin B are overexpressed during glioma progression, particularly at the leading edge of the tumor. In the present study, we simultaneously down-regulated uPAR and cathepsin B in SNB19 glioma cell monolayer or SNB19 spheroids using an adenoviral vector carrying antisense uPAR and antisense cathepsin B and a combination of these genes as determined by Western blot analysis. The Ad-uPAR-Cath B-infected cells revealed a marked reduction in tumor growth and invasiveness as compared with the parental and vector controls. In vitro and in vivo angiogenic assays demonstrated inhibition of capillary-like structure formation and microvessel formation after Ad-uPAR-Cath B infection of SNB19 cells when compared with Ad-cytomegalovirus (CMV)-infected or mock-infected controls. Furthermore, using a near infrared fluorescence probe, in vivo imaging for cathepsin B indicated low/undetectable levels of fluorescence after injection of the Ad-uPAR-Cath B construct into pre-established s.c. tumors as compared with Ad-CMV-treated and untreated tumors. The effect with bicistronic construct (Ad-uPAR-Cath B) was much higher than with single (Ad-uPAR/Ad-Cath B) constructs. These results indicate that the down-regulation of cathepsin B and uPAR plays a significant role in inhibiting tumor growth, invasion, and angiogenesis. Hence, the targeting of these two proteases may be a potential therapy for brain tumors and other cancers.
我们之前已经表明,尿激酶型纤溶酶原激活物受体(uPAR)和组织蛋白酶B在胶质瘤进展过程中过度表达,尤其是在肿瘤的前沿。在本研究中,我们使用携带反义uPAR和反义组织蛋白酶B的腺病毒载体以及通过蛋白质印迹分析确定的这些基因的组合,在SNB19胶质瘤细胞单层或SNB19球体中同时下调uPAR和组织蛋白酶B。与亲本细胞和载体对照相比,Ad-uPAR-Cath B感染的细胞显示肿瘤生长和侵袭性显著降低。体外和体内血管生成试验表明,与Ad-巨细胞病毒(CMV)感染或模拟感染的对照相比,Ad-uPAR-Cath B感染SNB19细胞后抑制了毛细血管样结构形成和微血管形成。此外,使用近红外荧光探针,与Ad-CMV处理和未处理的肿瘤相比,将Ad-uPAR-Cath B构建体注射到预先建立的皮下肿瘤中后,组织蛋白酶B的体内成像显示荧光水平较低/无法检测到。双顺反子构建体(Ad-uPAR-Cath B)的效果比单顺反子构建体(Ad-uPAR/Ad-Cath B)高得多。这些结果表明,组织蛋白酶B和uPAR的下调在抑制肿瘤生长、侵袭和血管生成中起重要作用。因此,靶向这两种蛋白酶可能是治疗脑肿瘤和其他癌症的潜在疗法。